Advertisement

Thyroid Cancer Benefits the Prognosis of Ovarian Cancer: A SEER-Based Study

  • Qiong Yang
  • Zhiyong Wu
  • Xujun He
  • Leibo Yu
  • Xiaofei Zhang
  • Kefeng LeiEmail author
Original Research

Abstract

Introduction

To explore the effect of a second thyroid cancer (TC) on ovarian cancer (OC) patient survival, we compared OC patients with or without a second primary TC using data from the Surveillance, Epidemiology, and End Results (SEER) database.

Methods

Data for OC only, female TC only and OC patients with a second TC (OC2TC) from two periods, 2000–2014 and 1980–1994, were extracted from the SEER database. Differences in clinicopathological and treatment characteristics were analysed using the chi-square test. Cox regression analyses were used to identify risk factors associated with OC survival. Disease-specific survival (DSS) and overall survival (OS) curves were compared using the log-rank test.

Results

There were 109 OC2TC patients from 2000 to 2014, and significant differences (P < 0.001) in the mean age at OC diagnosis, TNM stage and surgical history were found between OC and OC2TC patients. Several factors, including age, grade, TNM stage, histological type and surgical history, influenced OC survival (P < 0.001). OC2TC patients showed better survival than OC patients from 2000 to 2014, regardless of age, TNM stage or surgical history. However, this superiority was not significant in cases from 1980 to 1994 (P = 0.222 for OS).

Conclusion

Survival was better with OC2TC than with OC from 2000 to 2014 rather than 1980–1994, suggesting that TC improved the survival of OC patients from 2000 to 2014.

Keywords

Ovarian cancer Survival Thyroid cancer TSH suppression therapy 

Notes

Acknowledgements

Funding

This study was funded by the Natural Science Foundation of Zhejiang Province of China (grant numbers LY13H160039 and LY18H160039) and the Traditional Chinese Medicine Science and Technology Project of Zhejiang Province of China (grant number C-2013-W209). The sponsors also partially funded the article processing charges.

Editorial Assistance

This manuscript was edited for proper English language, grammar, punctuation, spelling, and overall style by one or more of the highly qualified native English-speaking editors at American Journal Experts.

Authorship

All named authors meet the International Committee of Medical Journal Editors (ICMJE) criteria for authorship for this article, take responsibility for the integrity of the work as a whole, and have given their approval for this version to be published.

Disclosures

Qiong Yang, Zhiyong Wu, Xujun He, Leibo Yu, Xiaofei Zhang and Kefeng Lei have nothing to disclose.

Compliance with Ethics Guidelines

All SEER data were accessed with approval from the SEER database and, as such, this article does not contain any studies with human participants or animals performed by any of the authors.

Data Availability

The datasets analysed during the current study are available from the corresponding author on reasonable request.

Supplementary material

12325_2019_918_MOESM1_ESM.tif (693 kb)
Supplementary material 1 (tif 693 kb)
12325_2019_918_MOESM2_ESM.tif (202 kb)
Supplementary material 2 (tif 202 kb)
12325_2019_918_MOESM3_ESM.tif (629 kb)
Supplementary material 3 (tif 630 kb)
12325_2019_918_MOESM4_ESM.tif (693 kb)
Supplementary material 4 (tif 693 kb)
12325_2019_918_MOESM5_ESM.docx (17 kb)
Supplementary material 5 (docx 18 kb)

References

  1. 1.
    Siegel RL, Miller KD, Jemal A. Cancer statistics, 2017. CA Cancer J Clin. 2017;67(1):7–30.  https://doi.org/10.3322/caac.21387.CrossRefGoogle Scholar
  2. 2.
    Howlader N, Noone A, Krapcho M, et al. SEER Cancer Statistics review, 1975–2014, based on November 2016 SEER data submission, posted to the SEER web site, April 2017. MD: National Cancer Institute Bethesda; 2017.Google Scholar
  3. 3.
    NCCN. National Comprehensive Cancer Network (NCCN) guidelines for OC, version 4.2017. 2017. https://www.nccn.org/professionals/physician_gls/pdf/ovarian.pdf. Accessed 9 Nov 2017.
  4. 4.
    Choi JH, Wong AS, Huang HF, Leung PC. Gonadotropins and ovarian cancer. Endocr Rev. 2007;28(4):440–61.  https://doi.org/10.1210/er.2006-0036.CrossRefGoogle Scholar
  5. 5.
    Jonsson JM, Skovbjerg Arildsen N, Malander S, et al. Sex steroid hormone receptor expression affects ovarian cancer survival. Transl Oncol. 2015;8(5):424–33.  https://doi.org/10.1016/j.tranon.2015.09.002.CrossRefGoogle Scholar
  6. 6.
    Zhao D, Zhang F, Zhang W, He J, Zhao Y, Sun J. Prognostic role of hormone receptors in ovarian cancer: a systematic review and meta-analysis. Int J Gynecol Cancer. 2013;23(1):25–33.  https://doi.org/10.1097/IGC.0b013e3182788466.CrossRefGoogle Scholar
  7. 7.
    Shi LF, Wu Y, Li CY. Hormone therapy and risk of ovarian cancer in postmenopausal women: a systematic review and meta-analysis. Menopause. 2016;23(4):417–24.  https://doi.org/10.1097/GME.0000000000000550.Google Scholar
  8. 8.
    Minlikeeva AN, Freudenheim JL, Cannioto RA, et al. History of thyroid disease and survival of ovarian cancer patients: results from the Ovarian Cancer Association Consortium, a brief report. Br J Cancer. 2017;117(7):1063–9.  https://doi.org/10.1038/bjc.2017.267.CrossRefGoogle Scholar
  9. 9.
    Journy NMY, Bernier MO, Doody MM, Alexander BH, Linet MS, Kitahara CM. Hyperthyroidism, hypothyroidism, and cause-specific mortality in a large cohort of women. Thyroid. 2017;27(8):1001–100.  https://doi.org/10.1089/thy.2017.0063.CrossRefGoogle Scholar
  10. 10.
    Agarwal R, Kaye SB. Prognostic factors in ovarian cancer: how close are we to a complete picture? Ann Oncol. 2005;16(1):4–6.  https://doi.org/10.1093/annonc/mdi104.CrossRefGoogle Scholar
  11. 11.
    Clark TG, Stewart ME, Altman DG, Gabra H, Smyth JF. A prognostic model for ovarian cancer. Br J Cancer. 2001;85(7):944–52.  https://doi.org/10.1038/sj.bjc.6692030.CrossRefGoogle Scholar
  12. 12.
    Hsieh MT, Wang LM, Changou CA, et al. Crosstalk between integrin alphavbeta3 and ERalpha contributes to thyroid hormone-induced proliferation of ovarian cancer cells. Oncotarget. 2017;8(15):24237-49. https://doi.org/10.18632/oncotarget.10757.CrossRefGoogle Scholar
  13. 13.
    Shinderman-Maman E, Cohen K, Weingarten C, et al. The thyroid hormone-alphavbeta3 integrin axis in ovarian cancer: regulation of gene transcription and MAPK-dependent proliferation. Oncogene. 2016;35(15):1977–87.  https://doi.org/10.1038/onc.2015.262.CrossRefGoogle Scholar
  14. 14.
    Shinderman-Maman E, Cohen K, Moskovich D, et al. Thyroid hormones derivatives reduce proliferation and induce cell death and DNA damage in ovarian cancer. Sci Rep. 2017;7(1):16475.  https://doi.org/10.1038/s41598-017-16593-x.CrossRefGoogle Scholar
  15. 15.
    Shinderman-Maman E, Weingarten C, Moskovich D, et al. Molecular insights into the transcriptional regulatory role of thyroid hormones in ovarian cancer. Mol Carcinog. 2017.  https://doi.org/10.1002/mc.22735.Google Scholar
  16. 16.
    Mazzaferri EL, Jhiang SM. Long-term impact of initial surgical and medical therapy on papillary and follicular thyroid cancer. Am J Med. 1994;97(5):418–28.CrossRefGoogle Scholar
  17. 17.
    Singer PA, Cooper DS, Daniels GH, et al. Treatment guidelines for patients with thyroid nodules and well-differentiated thyroid cancer American Thyroid Association. Arch Intern Med. 1996;156(19):2165–72.CrossRefGoogle Scholar
  18. 18.
    Cooper DS, Doherty GM, Haugen BR, et al. Management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid. 2006;16(2):109–42.  https://doi.org/10.1089/thy.2006.16.109.CrossRefGoogle Scholar
  19. 19.
    American Thyroid Association Guidelines Taskforce on Thyroid Nodules and Differentiated Thyroid Cancer, Cooper DS, Doherty GM, et al. Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid. 2009;19(11):1167-214. https://doi.org/10.1089/thy.2009.0110.CrossRefGoogle Scholar
  20. 20.
    Silva EG, Tornos C, Malpica A, Deavers MT, Tortolero-Luna G, Gershenson DM. The association of benign and malignant ovarian adenofibromas with breast cancer and thyroid disorders. Int J Surg Pathol. 2002;10(1):33–9.  https://doi.org/10.1177/106689690201000106.CrossRefGoogle Scholar
  21. 21.
    Carrera MP, Ramirez-Exposito MJ, Valenzuela MT, et al. Pyrrolidon carboxypeptidase activities in the hypothalamus–pituitary–thyroid and hypothalamus–pituitary–ovary axes of rats with mammary gland cancer induced by N-methyl nitrosourea. Horm Metab Res. 2005;37(2):74-8. https://doi.org/10.1055/s-2005-861158.CrossRefGoogle Scholar
  22. 22.
    Schneider G, Kopach K, Ohanian H, Bonnefond V, Mittler JC, Ertel NH. The hypothalamic-pituitary-gonadal axis during hyperthyroidism in the rat. Endocrinology. 1979;105(3):674–9.  https://doi.org/10.1210/endo-105-3-674.CrossRefGoogle Scholar

Copyright information

© Springer Healthcare Ltd., part of Springer Nature 2019

Authors and Affiliations

  1. 1.Department of General Surgery, Zhejiang Provincial People’s HospitalHangzhou Medical CollegeHangzhouChina
  2. 2.Department of Gynecology, Obstetrics and Gynecology HospitalFudan UniversityShanghaiChina
  3. 3.Key Laboratory of Gastroenterology of Zhejiang Province, Zhejiang Provincial People’s HospitalHangzhou Medical CollegeHangzhouChina
  4. 4.Department of PathologyDuke University Medical CenterDurhamUSA
  5. 5.Mechanical and Electrical Engineering InstituteJianghan UniversityWuhanChina
  6. 6.Department of General SurgeryThe 7th Affiliated Hospital of Sun Yat-Sen UniversityShenzhenChina

Personalised recommendations